Many recent studies have highlighted the importance of DNA repair pathways and the significance of PARP inhibitors. Using Homologous Recombination Deficiency (HRD) testing, ovarian and breast cancers are currently the most well studied for the subsequent use of PARP inhibitor (PARPi) therapy. More information is emerging regarding HRD testing in prostate and pancreatic cancers, and clinical trials for PARP inhibitor therapy applications in these diseases are underway as well. AMP subject matter experts will organize known scientific underpinnings and the most current research and clinical information into an up-to-date and useful three-part webcast series titled, “Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” This series will cover:
The targeted audience includes clinical laboratory professionals, oncologists, and genetic counselors as well as many other healthcare professionals engaged in the diagnosis, treatment, and care of cancer patients.
Webinar #2: Identifying Mutational Signatures of Homologous Recombination Deficiency to Predict PARPi Response.
Speaker: Peter Park, PhD
August 29, 2019
On-Demand Viewing Coming Soon!
Webinar #3: PARP Inhibitors in the Clinic: The Implications of Genetic Testing for Treatment Selection and Germline Counseling
Speakers: Katherine Nathanson, MD; Payal Shah, MD
October 22, 2019
This webinar series on PARP inhibitors is being planned and coordinated by the PARPi Content Committee:
Lynette Sholl, MD
Content Committee Chair
Brigham & Women's Hospital, Boston
Diana Mandelker, MD, PhD
Memorial Sloan Kettering Cancer Center, New York City
Tracy Stockley, PhD, FCCMG, FACMG
University Health Network, Toronto
and supported by the Association for Molecular Pathology (AMP) Training & Education Committee.
Supported by educational grants provided by AstraZeneca and Merck